PETMED EXPRESS INC
No enriched coverage for $PETS in the last 7 days.
No SEC Form 4 filings for $PETS in the last 30 days.
See all $PETS insider activity →PetMed Express reported Q1 2027 net sales of $41M, down 19.9% YoY, with a net loss of $6.1M. Key highlights include a $37M sale-leaseback deal, a partnership with Rural King, and an unsolicited acquisition offer of $3 per share. Management emphasized expense management and new revenue channels. Net sales stabilized above $40M sequentially, despite prescription sales declines.
PetMed Express, Inc. reported a Q1 2027 earnings call focused on shifting customer acquisition to diversified B2B and white-label offerings, after completing an SAP ERP rollout and new call center platform. Management cited a 15% acquisition cost reduction, delivery times improved up to 2 days, and recurring auto-ship and memberships at 61.5% of gross sales. Net loss was $6.1 million. It also disclosed an unsolicited $3/share acquisition proposal and a pending $37 million sale-leaseback.
PETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PetMeds® Announces First Quarter Financial Results Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. Quarterly Highl
Recent PETS coverage spans earnings, corporate actions and financial news.
Earnings beat on loss magnitude and liquidity boost may support short‑term price stability.
Operational reset and cost reduction plan could support margin trajectory, but near-term execution and rebate pressure remain key risks.
Results show sequential stabilization in sales and improved losses, but profitability remains negative and gross profit pressure persists.
The filing signals updated equity-compensation capacity for officers and directors, which can affect dilution expectations and incentive alignment.
The filing discloses a new real-estate monetization and leaseback structure that can affect near-term liquidity and future rent expense.
alphai scores every news story that mentions PETS with an AI model for sentiment and relevance, and aggregates insider trades from PETMED EXPRESS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
PetMed Express reported Q1 2027 net sales of $41M, down 19.9% YoY, with a net loss of $6.1M. Key highlights include a $37M sale-leaseback deal, a partnership with Rural King, and an unsolicited acquisition offer of $3 per share. Management emphasized expense management and new revenue channels. Net sales stabilized above $40M sequentially, despite prescription sales declines.
3 min readPetMed Express, Inc. reported a Q1 2027 earnings call focused on shifting customer acquisition to diversified B2B and white-label offerings, after completing an SAP ERP rollout and new call center platform. Management cited a 15% acquisition cost reduction, delivery times improved up to 2 days, and recurring auto-ship and memberships at 61.5% of gross sales. Net loss was $6.1 million. It also disclosed an unsolicited $3/share acquisition proposal and a pending $37 million sale-leaseback.
6 min readPETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PetMeds® Announces First Quarter Financial Results Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. Quarterly Highl
6 min readPETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On August 11, 2026, the shareholders of PetMed Express, Inc. (the “Company”), upon recommendation of the Company’s Board of
2 min readPETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. pets-20260723 0001040130 FALSE 0001040130 2026-07-23 2026-07-23 0001040130 us-gaap:CommonStockMember 2026-07-23 2026-07-23 0001040130 us-gaap:PreferredStockMember 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
5 min readPetMeds (PetMed Express, Inc., parent of PetCareRx, Nasdaq: PETS) said its new co-branded online pet pharmacy with Rural King is live via RuralKing.com and RuralKing.PetMeds.com. The platform offers pet medications, prescription food, preventatives and AutoShip for recurring needs. Intro offers include 25% off sitewide (RKPAW25) and 50% off first AutoShip (RKKING50).
4 min readPETMED EXPRESS INC (PETS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pets-20260623 0001040130 FALSE 0001040130 2026-06-23 2026-06-23 0001040130 us-gaap:CommonStockMember 2026-06-23 2026-06-23 0001040130 us-gaap:PreferredStockMember 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
2 min readNINA CAPITAL HOLDINGS INC. purchased 25,000 shares of PETMED EXPRESS INC (PETS) at $1.75 on 2026-06-08.
1 min readPetMed Express (PETS) reported fiscal 2026 net sales down 21.1% and a full-year net loss of $57.3 million, including $26.7 million goodwill impairment and $2.1 million inventory write-down, plus $4.5 million in non-recurring legal/severance costs tied to a whistleblower probe. The company said it regained regulatory compliance, fixed three material weaknesses, exited underperforming vendors for ~$6.1 million annualized savings, and saw its first Q4 sequential net sales increase since 2024.
4 min readPetMed Express Inc. (NASDAQ: PETS) stock has recently surged by 67.8%, driven by investor optimism and strategic moves, despite some financial setbacks. The company's introduction of a new Holiday Collection and the extension of its shareholder rights plan are seen as attempts to enhance value and protect against potential takeovers. While recent earnings showed a decrease in revenue and a detrimental profit margin, the steady gross margin and low valuation indicators suggest potential for a rebound.
4 min read
